A Multicenter, Randomized, Parallel-controlled Clinical Trial Protocol to Validate the Safety and Efficacy of a Steep Pulse Therapy System for the Treatment of Liver Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-16

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is a multicenter, randomized, parallel-controlled study. In this study, patients with liver cancer were selected as the research subjects, and the subjects were randomly divided into the experimental group and the control group. The experimental group used the steep pulse treatment system produced by Zhejiang CuraWay Medical Technology Co., Ltd., and the control group used the RF Ablation System produced by Covidien llc. A total of 5 or 9 visits were planned in this study, namely the screening period (-14-0 days), the day of the first ablation, 2 ± 1 days after the first ablation, 30 ± 5 days after the first ablation, and after the first ablation 90±7 days, the day of secondary ablation, 2±1 days after secondary ablation, 30±5 days after secondary ablation, and 90±7 days after secondary ablation. The complete ablation rate at 30 ± 5 days after the first ablation was used as the main efficacy evaluation index to evaluate the safety and efficacy of the steep pulse therapy system produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer

NCT04520906

Hepatocellular Carcinoma

TERMINATED NA

The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors

NCT07159048

Hepatocellular Carcinoma Colorectal Cancer Liver Metastasis

NOT_YET_RECRUITING NA

Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma

NCT04526080

Hepatocellular Carcinoma

WITHDRAWN PHASE2

A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC

NCT03116984

Hepatocellular Carcinoma

UNKNOWN PHASE3

Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge

NCT03277716

Hepatocellular Carcinoma Non-resectable Transarterial Chemoembolization Microwave Ablation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

A Steep Pulse Therapy System for the Treatment of Liver Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Steep Pulse Therapy System

Group Type EXPERIMENTAL

steep pulse therapy system

Intervention Type DEVICE

The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation

RF Ablation System

Group Type ACTIVE_COMPARATOR

RF Ablation System

Intervention Type DEVICE

RF Ablation System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

steep pulse therapy system

The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation

Intervention Type DEVICE

RF Ablation System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The age of the patient is between 18-80 years old, and the gender is not limited.
2. For clinically diagnosed liver tumors, the diameter of a single tumor is less than or equal to 5cm; for multiple tumors: the number of tumors is not more than 3, and the largest tumor diameter is less than or equal to 3cm.
3. Patient is able to take care of himself, and ECOG performance status is between 0 and 2 points.
4. Liver function classification Child-Pugh A or B.
5. Expected survival period ≥ 6 months.
6. Patient is able to understand and comply with the trial protocol, and sign the informed consent.

Exclusion Criteria

1. It is less than 30 days after the end of chemotherapy, radiotherapy, immunotherapy, or targeted therapy.
2. Within 3 months after ablation, patients need to continue treatment with chemotherapy, radiation therapy, immunotherapy, targeted therapy, surgery, or other minimally invasive modalities.
3. patients with severe infectious diseases such as bacteremia and toxemia.
4. patients with uncorrectable coagulation dysfunction (PLT\<40xl09/L).
5. patients with severe heart, brain, lung and other diseases, and patients with severe arrhythmia.
6. patients with implanted artificial hearts, lungs, internal pulse regulators or wearable medical electronic devices such as electrocardiography.
7. Patients with a history of epilepsy.
8. Patients with acute myocardial infarction within 6 months.
9. Pregnant and lactating women and those who plan to become pregnant within one year.
10. Those who are allergic to ultrasound, CT or MRI contrast agents.
11. Those who are contraindicated in general anesthesia.
12. Those who have participated in clinical trials of any drug or medical device within the first 3 months of the group.
13. The researchers believe that there are other factors that are not suitable for inclusion or that affect the participation of subjects in the study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No